London, United Kingdom
Onyvax is a biotechnology startup based in the United Kingdom, founded in 1997. The company focuses on developing new cancer therapies that harness the selective power of the immune system to seek out and destroy tumor cells. Their products specifically target cancer cells, aiming to increase effectiveness while minimizing side effects associated with conventional treatments. Onyvax's lead product is in clinical trials for the treatment of prostate cancer and is poised to enter the final stages of development.
Onyvax's commitment lies in the commercialization of novel therapies that enhance survival while maintaining a high quality of life for patients. The company has collaborations with leading hospitals and other institutions throughout Europe and the US. The latest investment in Onyvax was a £8.00M Series C investment at 08 May 2006, led by 3i Group, Alice Ventures, Alta Berkeley Venture Partners, SR One, and Excalibur Fund Managers.
